Telitacicept Improves Clinical Response in Active SLE
In a 52-week trial, telitacicept produced a higher clinical response rate in patients with active systemic lupus erythematosus (SLE) compared to placebo.
Patients treated with telitacicept achieved significantly greater improvements in disease activity scores, reflecting better control of lupus manifestations such as rash, arthritis, and serologic activity.
However, the treatment was also linked to increased rates of upper respiratory infections, decreased immunoglobulin levels, and injection-site reactions.
The trial demonstrated that telitacicept’s mechanism—targeting both BAFF and APRIL pathways—effectively suppresses B-cell overactivation, a key driver of autoimmunity in SLE.
The study highlights the need for careful monitoring due to potential side effects.
Author summary: Telitacicept improves SLE response rates.
More News
- What Mavericks’ Anthony Davis said after getting shut down by Thunder
- Mavericks Slow Vikings, End Home-Court Winning Streak, 60-55
- Anthony Davis (Mavericks) sur les tablettes des Bulls ?
- Hudson’s Bay Downtown Vancouver Store for Sale
- Should you start or sit Justin Jefferson vs. Commanders?
- Thomas Jefferson University Overview
- [JEFFERSON PARISH LANDFILL DROP-OFF SITE CLOSED TO PUBLIC FOR REMAINDER OF THE DAY]
- Brasero Extérieur RedFire Irving medium black
- Jefferson boys wrestling beats rival Alameda in pin-fest
- Singer/Songwriter Sydney Irving releases new music video for "Something Better" from acclaimed album UNFASHIONED CREATURES on DEKO Entertainment / Warner Music Group - ADA